izpis_h1_title_alt

AKR1B1 as a prognostic biomarker of high-grade serous ovarian cancer
ID Hojnik, Marko (Author), ID Kenda Šuster, Nataša (Author), ID Smrkolj, Špela (Author), ID Sisinger, Damjan (Author), ID Frković-Grazio, Snježana (Author), ID Verdenik, Ivan (Author), ID Lanišnik-Rižner, Tea (Author)

.pdfPDF - Presentation file, Download (6,42 MB)
MD5: 920A293BA8A0DE460E8FDC8742131FEF
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/14/3/809 This link opens in a new window

Abstract
Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.

Language:English
Keywords:high-grade serous ovarian cancer, immunohistochemistry, survival, prognosis, biomarker, aldo-keto reductase family 1 member B1 (AKR1B1), aldo-keto reductase family 1 member B10 (AKR1B10), resistance
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:15 str.
Numbering:Vol. 14, iss. 3, art. 809
PID:20.500.12556/RUL-137350 This link opens in a new window
UDC:618.1
ISSN on article:2072-6694
DOI:10.3390/cancers14030809 This link opens in a new window
COBISS.SI-ID:96813059 This link opens in a new window
Publication date in RUL:13.06.2022
Views:505
Downloads:103
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:05.02.2022

Secondary language

Language:Slovenian
Keywords:serozni rak jajčnikov visoke stopnje, imunohistokemija, preživetje

Projects

Funder:ARRS - Slovenian Research Agency
Project number:J3-8212
Name:Vloga intrakrinega delovanja estrogenov pri hormonsko odvisnih boleznih – pomen za zdravljenje

Funder:ARRS - Slovenian Research Agency
Project number:J3-2535
Name:Vloga androgenov pri hormonsko odvisnih boleznih: pomen za diagnostiko in zdravljenje

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back